Riamilovir sodium hydrate - CAS# 928659-17-0 0072 Smiles: CN(C1C=CC(=CC=1)C(F)(F)F)S(=O)(=O)C1C=CC(=CC=1)C(=O)NC1=NC(=CS1)C1=CC=CC=N1

Smiles: CN(C1C=CC(=CC=1)C(F)(F)F)S(=O)(=O)C1C=CC(=CC=1)C(=O)NC1=NC(=CS1)C1=CC=CC=N1

eplepsyres

4SC-202 shows a broad anti-proliferative activity towards human cancer cell lines with a mean IC50 of 0

and the human first apoptosis signal (Fas) intracellular domain

PMID: 31826639

Riamilovir sodium hydrate - CAS# 928659-17-0 0072 Smiles: CN(C1C=CC(=CC=1)C(F)(F)F)S(=O)(=O)C1C=CC(=CC=1)C(=O)NC1=NC(=CS1)C1=CC=CC=N1Riamilovir sodium hydrate, CAS No. 928659 17 0, also known as Triazavirin, is an antiviral drug candidate. Tiazavirin is a broad spectrum antiviral drug developed in Russia. It has a novel triazolotriazine core, which represents a new structural class of non nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti